targeted-therapy

You have access
Microcystin LR Shows Cytotoxic Activity Against Pancreatic Cancer Cells Expressing the Membrane OATP1B1 and OATP1B3 Transporters
VALENTINOS KOUNNIS, GEORGIOS CHONDROGIANNIS, MICHALIS D. MANTZARIS, ANDREAS G. TZAKOS, DEMOSTHENES FOKAS, NIKOLAOS A. PAPANIKOLAOU, VASILIKI GALANI, IOANNIS SAINIS and EVANGELOS BRIASOULIS

Anticancer Research November 2015, 35 (11) 5857-5865;
You have access
Tissue Biomarkers in Predicting Response to Sunitinib Treatment of Metastatic Renal Cell Carcinoma
IVAN TRÁVNÍČEK, JINDŘICH BRANŽOVSKÝ, KRISTÝNA KALUSOVÁ, ONDŘEJ HES, LUBOŠ HOLUBEC, KEVIN BAULETH PELE, TOMÁŠ ÜRGE and MILAN HORA

Anticancer Research October 2015, 35 (10) 5661-5666;
You have access
Phase I Study of Everolimus, Cetuximab and Irinotecan as Second-line Therapy in Metastatic Colorectal Cancer
J. RANDOLPH HECHT, TONY R. REID, CHRISTOPHER R. GARRETT, J. THADDEUS BECK, SHELDON J. DAVIDSON, MARY J. MACKENZIE, ULRIKE BRANDT, SYED RIZVI and SUNIL SHARMA

Anticancer Research March 2015, 35 (3) 1567-1573;
You have access
Matched-pair Analysis of Dendritic Cell Versus Targeted-therapy in Patients with Metastatic Renal Cell Carcinoma
ALEXANDER ISAAK, STEFAN HAUSER, SEBASTIAN ROGENHOFER and INGO G.H. SCHMIDT-WOLF

Anticancer Research March 2015, 35 (3) 1575-1582;
You have access
Gene Mutations in Squamous Cell NSCLC: Insignificance of EGFR, KRAS and PIK3CA Mutations in Prediction of EGFR-TKI Treatment Efficacy
ONDREJ FIALA, MILOS PESEK, JINDRICH FINEK, LUCIE BENESOVA, ZBYNEK BORTLICEK and MAREK MINARIK

Anticancer Research April 2013, 33 (4) 1705-1711;

Main menu

User menu

Search

targeted-therapy